Phase I pharmacokinetic study of dasatinib (BMS-354825) in patients with advanced malignancies and varying levels of liver dysfunction: S0711, a SWOG early therapeutics committee study.
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: John Sarantopoulos, Antje Hoering, Timothy W. Synold, Devalingam Mahalingam, Ding Wang, Heinz-Josef Lenz, Pat O'Rourke, Rachel Sexton, Peter J. Van Veldhuizen, Monica M. Mita, Lucas Wong, Alain C. Mita, Anthony B. El-Khoueiry, Vincent M. Chung, David R. Gandara, Sheela Tejwani, Naoko Takebe, Chris H.M. Takimoto, S. Percy Ivy, Razelle Kurzrock
Institutions: The University of Texas at San Antonio Health Science Center, City Of Hope National Medical Center, City of Hope, Henry Ford Health, Henry Ford Hospital, USC Norris Comprehensive Cancer Center, The University of Kansas Cancer Center, UC Davis Comprehensive Cancer Center, University of California, Davis, The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2601082076